Synapse - Theresa Davey

Results (22)

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas

Meeting Abstract

Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas

Meeting Abstract

Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
Blood (2019)

Fulltext@MSK | Save

Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma

Meeting Abstract

Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
Blood (2019)

Fulltext@MSK | Save

High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
Blood (2019)

Fulltext@MSK | Save

A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma

Meeting Abstract

Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
Blood (2019)

Fulltext@MSK | Save

The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts

Meeting Abstract

Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
Blood (2018)

Fulltext@MSK | Save